Stay updated on Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check5 days agoChange DetectedThe page shows an updated revision tag from v3.6.4 to v3.6.5, indicating a versioned update to the site content. This appears to be a maintenance/update change in the content management system rather than a substantive modification to the study details.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page revision label was updated from v3.6.3 to v3.6.4, signaling a minor refresh of the study record.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedThe page footer now shows Revision: v3.6.3, replacing Revision: v3.6.2, indicating a small software update to the page. It does not alter the study content or displayed information.SummaryDifference0.1%

- Check47 days agoChange DetectedThe revision label on the page updated from v3.6.0 to v3.6.2, indicating a software update. The study content and navigation remain unchanged.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded several user assistance sections (How to Read a Study Record, Common Questions, How to Join a Study) and clarified the Intervention/Treatment header, improving navigation and clarity of what the study involves. The change also introduces a recruitment status note ('No longer looking for participants') and updates the page revision tag (from v3.5.5 to v3.6.0), reflecting an overall update to the study page.SummaryDifference0.5%

- Check69 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, representing a minor version update to the site's study record.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.